Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose

Trial Profile

Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Epistaxis; Hereditary haemorrhagic telangiectasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 18 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top